Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Policy / Regulatory

Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation

Fineline Cube Aug 19, 2026
Company Drug

Shanghai Yizhong Pharmaceutical’s YXC‑002 Wins IND Approval – Fourth‑Generation Brain‑Penetrant EGFR‑TKI for Non‑Small Cell Lung Cancer Overcomes C797S Resistance

Fineline Cube Aug 19, 2026
Company Drug

Genrix Bio’s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B – TCR‑Mimic T‑Cell Engager Targets HBV‑Infected Hepatocytes

Fineline Cube Aug 19, 2026
Policy / Regulatory

NHC, NDRC Issue Guidelines to Boost China’s Birth Rates with Reproductive Support Measures

Fineline Cube Aug 19, 2022

The National Health Commission (NHC) and National Development and Reform Commission (NDRC), along with multiple...

Company Deals

Biocytogen Pharmaceuticals Makes HKSE Debut with USD 70 Million IPO

Fineline Cube Aug 19, 2022

Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public...

Company Drug

CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study

Fineline Cube Aug 19, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...

Company Deals

Jemincare Licenses Oral Androgen Receptor Degrader to Roche’s Genentech

Fineline Cube Aug 18, 2022

China-based Jiangxi Jemincare Group has entered into a licensing agreement with Swiss giant Roche’s Genentech....

Company Drug R&D

Spinraza’s NRDL Inclusion Boosts SMA Patient Treatment in China

Fineline Cube Aug 18, 2022

The Meier Advocacy & Support Center for Spinal Muscular Atrophy (SMA) and the Shenzhen Research...

Policy / Regulatory

CDE Releases Draft Guidelines for RWE-Backed Drug Registration Applications

Fineline Cube Aug 18, 2022

The Center for Drug Evaluation (CDE) has released a notification regarding the “Real-World Evidence (RWE)-backed...

Drug

ICT’s GCC19CART Enters US Phase I Study for Colorectal Cancer

Fineline Cube Aug 18, 2022

Sino-US firm Innovative Cellular Therapeutics (ICT) announced the involvement of the first subject in a...

Drug

BRL Medicine’s BRL-101 Receives Clinical Trial Approval for Beta-Thalassemia

Fineline Cube Aug 18, 2022

Shanghai-based BRL Medicine Inc. has announced that it has received clinical trial approval from the...

Company Legal / IP

GenScript Biotech Sues Former CSO Fan Xiaohu for Trade Secret Infringement

Fineline Cube Aug 18, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has sued its former...

Company Drug

Innovent Biologics Initiates Phase I Study of IBI311 for Thyroid-Associated Ophthalmopathy

Fineline Cube Aug 18, 2022

China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...

Company Digital Hospital

Baidu Health’s Precision Matching Engine Powers Public Hospitals

Fineline Cube Aug 18, 2022

China Internet giant Baidu’s one-stop health management platform Baidu Health has updated the status of...

Company

WuXi Biologics’ Revenues Surge 63.5% in H1 2022 on Strong CRDMO Growth

Fineline Cube Aug 18, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKEX: 2269) published its unaudited...

Company Deals

MingMed Biotech’s Hong Kong IPO Signals Push for First-in-Class Drugs

Fineline Cube Aug 18, 2022

Guangzhou-based MingMed Biotech has officially made an initial public offering (IPO) to the Hong Kong...

Company Drug

Junshi Biosciences’ JunMaiKang Biosimilar Gets NMPA Approval Filing

Fineline Cube Aug 18, 2022

China-based Junshi Biosciiences (HKG: 1877, SHA: 688180) has announced that another market approval filing for...

Company Deals

Applied Protein Technology Raises Hundreds of Millions in Series B Funding

Fineline Cube Aug 17, 2022

Shanghai-based Applied Protein Technology (APT Bio), a biotech company focused on mass spectrometry multi-omics precision...

Company Deals Drug

SciClone Licenses Menarini’s Vaborem to Tackle Drug-Resistant Infections in China

Fineline Cube Aug 17, 2022

SciClone Pharmaceuticals Inc (Nasdaq: SCLN), a China-based company since going private in 2017, announced a...

Company Drug

Zelgen Biopharmaceuticals’ ZGGS18 Receives NMPA Approval for Solid Tumor Treatment

Fineline Cube Aug 17, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...

Company Deals

Fortune Care Raises Hundreds of Millions in Series B for Elderly Care Expansion

Fineline Cube Aug 17, 2022

Fushoukang (Shanghai) Family Services Co., Ltd, also known as Fortune Care, a Shanghai-based smart elderly...

Medical Device

Bio-Heart’s BIOHEART-II Study Meets Primary Endpoint for Bioresorbable Scaffolds

Fineline Cube Aug 17, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) announced that the BIOHEART-II study for...

Company

Sihuan Pharmaceutical Restructures with Dual Organization Model

Fineline Cube Aug 17, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced a structural reshuffling, setting up a...

Posts pagination

1 … 679 680 681 … 710

Recent updates

  • Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation
  • Shanghai Yizhong Pharmaceutical’s YXC‑002 Wins IND Approval – Fourth‑Generation Brain‑Penetrant EGFR‑TKI for Non‑Small Cell Lung Cancer Overcomes C797S Resistance
  • Genrix Bio’s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B – TCR‑Mimic T‑Cell Engager Targets HBV‑Infected Hepatocytes
  • Novo Nordisk China Launches Organizational Restructuring – Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division
  • Nhwa Pharmaceutical Wins NMPA IND Approval for Two Category 1 Chemical Drugs – NH130 for Schizophrenia & Alzheimer’s Psychosis, NH302 for Acute Pain
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation

Company Drug

Shanghai Yizhong Pharmaceutical’s YXC‑002 Wins IND Approval – Fourth‑Generation Brain‑Penetrant EGFR‑TKI for Non‑Small Cell Lung Cancer Overcomes C797S Resistance

Company Drug

Genrix Bio’s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B – TCR‑Mimic T‑Cell Engager Targets HBV‑Infected Hepatocytes

Company

Novo Nordisk China Launches Organizational Restructuring – Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.